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Background: The Li-Fraumeni syndrome (LFS) is an inherited rare cancer predisposition syndrome characterized by
a variety of early-onset tumors. Although germline mutations in the tumor suppressor gene TP53 account for over
50% of the families matching LFS criteria, the lack of TP53 mutation in a significant proportion of LFS families,
suggests that other types of inherited alterations must contribute to their cancer susceptibility. Recently, increases
in copy number variation (CNV) have been reported in LFS individuals, and are also postulated to contribute to LFS
phenotypic variability.
Methods: Seventy probands from families fulfilling clinical criteria for either Li-Fraumeni or Li-Fraumeni-like
(LFS/LFL) syndromes and negative for TP53 mutations were screened for germline CNVs.
Results: We found a significantly increased number of rare CNVs, which were smaller in size and presented higher
gene density compared to the control group. These data were similar to the findings we reported previously on a
cohort of patients with germline TP53 mutations, showing that LFS/LFL patients, regardless of their TP53 status, also
share similar CNV profiles.
Conclusion: These results, in conjunction with our previous analyses, suggest that both TP53-negative and positive
LFS/LFL patients present a broad spectrum of germline genetic alterations affecting multiple loci, and that the
genetic basis of LFS/LFL predisposition or penetrance in many cases might reside in germline transmission of CNVs.
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Li-Fraumeni syndrome (LFS) is an inherited condition
characterized by early-onset sarcoma, brain, breast and
other cancers. Families with incomplete LFS features are
referred to as Li-Fraumeni-like (LFL) [1,2]. Germline
mutations in the tumor suppressor gene TP53 account
for over 50% of the families matching LFS criteria [3]
but for only 20-40% of the LFL families [4]; lack of TP53
mutation in a significant proportion of LFS/LFL families,
suggests that other types of inherited alterations must
contribute to their cancer susceptibility. Although point* Correspondence: amandagonc@yahoo.com
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unless otherwise stated.mutations have been commonly described, DNA copy
number variations (CNVs) have been reported as an
alternative mechanism for cancer predisposition for at
least 30% of known Mendelian cancer genes [5,6],
including TP53 [7,8], APC [9], BRCA1 [10] and the mis-
match repair gene MSH2 [9].
We used microarray-based comparative genomic
hybridization (array-CGH) to screen for CNVs in the
germline DNA of 70 patients fulfilling diagnostic criteria
for LFS or LFL, but with no detectable mutation invol-
ving TP53 [11]. Results were compared to a random
sample of 100 Brazilian control individuals [12], to a
sample of LFS/LFL TP53 mutated patients previously
published by us [13], and to publically available CNV
data in normal individuals (DGV).d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Patients
The patients were recruited and ascertained at the Depart-
ment of Oncogenetics of the A. C. Camargo Cancer Center,
São Paulo, Brazil. The protocol was approved by the ethics
committee of the institution and informed consent ob-
tained from all subjects and their families. DNA was iso-
lated from peripheral leukocytes using standard protocols.
The cohort comprised 70 non-related probands fulfilling
either the classical definition of LFS or at least one of the
clinical criteria commonly defining LFL (Chompret, Birch
or Eeles’s definitions) [14-17]. These DNA samples had
been previously shown to have no mutations in the coding
sequences (exons 2 to 11) or splice junctions of the TP53
gene [18].
Controls
The CNV data of a group of 100 individuals randomly se-
lected from the urban area of São Paulo, Brazil, was used
as control for this study as previously described [12].
Array-CGH
Array-CGH was performed using a 180 K whole-genome
platform (design 22060, Agilent Technologies, Santa
Clara, USA), with an average spacing of 18 Kb between
probes. Scanned images of the arrays were processed and
analyzed using Feature Extraction software and Genomic
Workbench software (both from Agilent Technologies),
together with the statistical algorithm ADM-2, and using
a sensitivity threshold of 6.7. We applied a ‘loop design’ in
our hybridizations as previously described [19], resulting
in two reverse labeling hybridizations per sample. Alte-
rations had to encompass at least three consecutive
probes with aberrant log2 values to be called by the soft-
ware, and those not detected in both dye-swap experi-
ments were excluded from the analysis.
Analysis
The detected copy number variations were compared to
CNVs reported in the Database of Genomic Variants
(DGV; http://dgv.tcag.ca/dgv/app/home; freeze December,
2011). We arbitrarily classified CNVs into “rare” and “com-
mon” by considering as “rare” those CNVs encompassing
coding sequences and present in frequencies < 0.1% in
DGV, that does not exclude that some rare CNVs might
contain smaller segments which can vary in copy number
in the population. Mann–Whitney and Fisher-exact tests
were used to compare patients and controls for frequency,
gene density and size distribution of CNVs.
Gene annotation was performed using the University
of California Santa Cruz Genome Browser (UCSC) and
the Catalog of Somatic Mutations (COSMIC; http://
cancer.sanger.ac.uk/cancergenome/projects/cosmic/).Results
The clinical classification of the patients, description of
their cancer types and age at onset are given in Additional
file 1: Table S1. A total of 567 CNVs were identified in the
70 patients investigated (308 losses and 259 gains). Table 1
presents the CNV features detected in the LFS/LFL pa-
tients without TP53 mutations, the previously published
CNV data from LFS/LFL patients with mutation [13] and
controls. Full CNV data are presented in Additional file 2:
Table S2.
No significant differences were found between the
TP53-negative patients compared to controls regarding
the number of common CNVs per genome or ratio of
losses to gains. However, there was a significantly higher
number of rare CNVs per genome in this patient group
(p = 0.014; Mann–Whitney test) (Figure 1A). With respect
to CNV size, the CNVs in the TP53-negative patients were
significantly smaller than controls both for common
(Figure 1B) and rare (Figure 1C) CNVs (p < 0.001; Mann–
Whitney test).
Furthermore, the mean number of genes encompassed
by rare alterations per Mb (gene density) was much
higher in patients with 31 genes per Mb as opposed to 9
in controls (p < 0.0001; Mann Whitney test) (Figure 1D).
In addition, while no recurrence was found among the
rare CNVs in control individuals, 4 rare CNV regions
were either recurrent or partially overlapping in 2 inde-
pendent patients for each region (Table 2).
Discussion
Despite extensive search for other genes underlying LFS/
LFL, no genes other than TP53 have been consistently
associated with this complex syndrome. However, pa-
tient series in the US and Europe have shown that only
~ 30% of those subjects tested for TP53 mutation be-
cause of familial predisposition or early-onset of cancer
turned out to be positive. This strongly suggests that
genetic factors other than TP53 mutations must be con-
tributing to familial predisposition cancer in many LFS/
LFL subjects.
We previously described an increased number of
CNVs in Brazilian Li-Fraumeni patients carrying germ-
line mutations in the TP53 gene, and also reported an
increased number of rare CNVs per genome in patients
carrying mutations that affected the DNA binding do-
main (DBD) of the TP53 gene compared to both con-
trols and p.R337H mutants [13]. The Brazilian founder
mutation p.R337H has a markedly less severe impact on
tumor predisposition [20,21] and has a CNV profile
much closer to controls than the TP53 DBD mutations
[13]. A similar, but milder increase in number of rare
CNVs was observed among non-mutated patients. In a
previous article [13], we speculated that an increase of
rare CNVs could result from inefficient selection against
Table 1 Features of the detected CNVs in TP53 mutated and non-mutated patients compared to controls: size, number of genes, and gene density
TP53 type of
mutation
Number of
individuals
Number of CNVs
(rare/common)
Mean number of
common CNVs
Mean size of
common CNVs (Kb)
Gene density of
common CNVs
(gene number/Mb)
Mean number
of rare CNVs
Mean size of
rare CNVs (Kb)
Gene density
of rare CNVs
(gene number/Mb)
TP53- mutated* DNA binding domain 9 10/56 7.33 ± 2.5 165.0 ± 233.3 14.0 1.11 ± 1.2
(p = 0.0086)
168.7 ± 202.8 15.4 (p = 0.0159)
R337H 12 3/89 7.67 ± 2.1 186.6 ± 343.0 (p = 0.0032) 10.4 0.25 ± 0.6 204 ± 161.6 8.1
All 21 13/145 7.6 ± 2.3 178.2 ± 304.6 (p = 0.0022) 12.8 0.65 ± 1.0 176.8 ± 188.3 13.4 (p = 0.0367)
TP53-wild type 70 40/527 7.5 ± 2.6 208.7 ± 459.9 (p = 0.0008) 9.0 0.57 ± 0.9
(p = 0.0145)
94.5 ± 101.8
(p = 0.0001)
31.4 (p = 0.0001)
Controls 100 23/679 6.7 ± 3.0 236.7 ± 454.0 8.8 0.23 ± 0.4 232.2 ± 152.7 8.6
*Previously published results [13].
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Figure 1 Comparison between the CNVs in Li-Fraumeni patients and controls. (A) Frequency of rare CNVs; (B) Size of common CNVs;
(C) Size of rare CNVs; (D) Gene density in LFS patients and controls. Mann-Whitney test; *p =0.014; ***p < 0.001, ****p < 0.0001.
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tosis driven by TP53 germline mutations. Similarly, in
this new study of TP53-negative patients, increases in
the number of rare CNVs could result from mutations
in genes other than TP53, possibly in the TP53 pathway,
as previously suggested [22-24]. Such an example was
recently reported by us [25] in a patient of the present
cohort and involved the deletion of the full BAX gene,
which is directly activated by the TP53 protein. The very
high gene content of rare CNVs in TP53-negative
patients (an almost four-fold increase compared to con-
trols) suggests that these CNVs are under strong se-
lective pressure, and that their gene content likelyTable 2 Recurrent CNV regions in patients without TP53 muta
Chr Start
position
End
position
Type Size Genes associated
chrX 148653235 148789920 Gain 136685 HSFX1, HSFX1, MAGEA
chrX 148638057 148835731 Gain 197674 HSFX1, HSFX1, MAGEA
chr19 2173067 2187671 Gain 14604 DOT1L, PLEKHJ1, hsa-m
chr19 2173067 2187671 Loss 14604 DOT1L, PLEKHJ1, hsa-m
chr5 140207385 140243110 Gain 35725 PCDHA11, PCDHA12, P
chr5 140207385 140243110 Loss 35725 PCDHA11, PCDHA12, P
chr7 2182941 2234914 Gain 51973 MAD1L1
chr7 2182941 2244756 Loss 61815 MAD1L1, FTSJ2
STS – soft tissue sarcoma.contribute to oncogenesis. Interestingly, TP53-mutated
patients also exhibit increased gene density, although
this phenomenon is much less striking than in the non-
mutated patients (Table 1). These results show that LFS/
LFL patient’s, with the exception of those carrying the
p.R337H mutation, share similar CNV profiles regardless
of their mutation status.
The recurrent regions detected in the rare CNVs in
our study encompass several genes with potential func-
tional relevance to carcinogenesis, including MAD1L1,
DOT1L1, MAGEA8 and MAGEA9. MAD1L1 encodes a
protein that plays an important role in maintaining
spindle checkpoint functions and alterations in this genetion
Patient Tumor Age of
onset
Tumor Age of
onset
9, MAGEA8 Y0123T000 Breast 37 Breast 37
9, MAGEA8 Y006T00 STS 15 Breast 32
ir-1227 Y101T000 Breast 48 Thyroid 52
ir-1227 Y0114T000 Osteosarcoma 30
CDHA13 Y0110T000 Breast 36
CDHA13 Y0112T000 Breast 34
Y0143T000 Breast 42
Y0123T000 Bilateral breast 37, 37
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cancers [26,27]. The histone methyltransferase DOT1L1 is
involved in leukemia [28]. The MAGE gene family encodes
proteins only expressed on normal germ cells of the testis
but are ectopically expressed in melanomas and in a variety
of other common cancer types [29]. Although the fre-
quency of each recurrent region is individually low, as a
group, rare CNVs may represent a significant contributor
to the etiology of LFS/LFL.
Although the potential role of CNVs as genetic risk fac-
tors to cancer predisposition has not yet been fully defined,
there is now compelling evidence that cancer-related genes
may be encompassed or overlapped by common CNVs.
Shlien et al. [30] found a significant enrichment of CNVs in
LFS probands; among the genes encompassed by common
CNVs, they reported recurrence of a duplication of MLLT4,
a target of the RAS pathway. In agreement with this, we
also detected common MLLT4 duplications in three of the
TP53-negative patients but none in the controls. We have
also recently reported a 691 kb recurrent deletion at 7q34
harboring only the PIP and TAS2R39 genes [31] in five
patients with high cancer predisposition from different
cohorts, including two TP53-negative patients from the
present study and one TP53-positive LFS patient. Common
cancer CNVs, such as the ones harboring MLLT4 and PIP,
most likely confer a minor increase in disease risk that col-
lectively or in association with highly penetrant mutations
may cause a substantially elevated risk.
Conclusion
These findings support the hypothesis that in LFS/LFL
families not carrying TP53 mutations, cancer predis-
position may be caused by a broad spectrum of genetic al-
terations affecting multiple loci. How CNVs and other
genetic modifiers interact and modulate TP53 tumor sup-
pressor activities remain to be determined. Elucidating
these mechanisms may hold the key to define evidence-
based strategies for counseling using combined risks from
TP53 and other variants, including CNVs.
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